Kornimate/medical-research-clean huggingface dataset:
impact of scapular mobilization and strengthening exercises on shoulder function post mastectomy

Conditions: Oncologic Complications; Exercise Therapy; Shoulder Pain; Shoulder Syndrome

Summary: the most common complications following mastectomy are pain, lymphedema of the upper limb ipsilateral to surgery, decreased range of motion (rom), limited to 90° of flexion, abduction, and external rotation to 40° of the shoulder, and postural changes. it was reported that 60% of breast cancer patients show a reduction in shoulder flexion and abduction at 1-month post-surgery and 10% of survivors show a persistent rom reduction at 12 months. so, the purpose of the study was to evaluate the therapeutic impact of scapular mobilization and strengthening exercises on shoulder function post-mastectomy.

in this randomized controlled trial study (rct), forty female patients "the patient's ages ranged from 40 to 55 years" suffering from post-mastectomy shoulder dysfunction ((20° ≥ rom limitation compared to the sound shoulder \& 3 months to 6 months post mastectomy) were randomly assigned into two equal groups, each one had 20 patients. group a (study group): this group included 20 patients with shoulder dysfunction post-mastectomy who received scapular mobilization and strengthening exercise in addition to their conventional physical therapy program for four weeks, three sessions/week. group b (control group): this group included 20 patients with shoulder dysfunction who received conventional physical therapy programs in form of joint mobilization, posterior capsule stretching, and range of motion exercise (rom) for four weeks, 3 sessions/week. equipment and tools: * measurement tools were (the shoulder pain and disability index (spadi): for measurement of shoulder disability and inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation), the measurements were recorded before and after the study. * therapeutic equipment and tools were (thera bands of different colors and resistance and dumbbells of different weights). the potential participants were excluded if they met any of the following criteria: diseases such as rheumatoid arthritis, history of trauma or accidental injuries, neurological involvement (stroke, parkinsonism), history of surgery on the involved shoulder, and diabetic patient.

Eligibility criteria:
inclusion criteria: * female patients with ages ranging from 40-55 years. * all patients had shoulder dysfunction post-mastectomy (20° ≥ rom limitation compared to the sound shoulder). * patients were 3 months to 6 months post-mastectomy. * all enrolled patients signed the informed consent. exclusion criteria: * disease such as rheumatoid arthritis. * history of trauma or accidental injuries. * neurological involvement (stroke, parkinsonism). * history of surgery on the involved shoulder. * diabetic patient.

Keywords: scapular mobilization scapular strengthening exercises mastectomy shoulder function
a study of ixekizumab (ly2439821) in children with juvenile idiopathic arthritis categories of enthesitis-related arthritis (including juvenile onset ankylosing spondylitis) and juvenile psoriatic arthritis

Conditions: Juvenile Psoriatic Arthritis; Enthesitis Related Arthritis

Summary: the reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (jia) categories of enthesitis-related arthritis (era) (including juvenile onset ankylosing spondylitis \[joas\]) and juvenile psoriatic arthritis (jpsa).


Eligibility criteria:
inclusion criteria: * participants must have active juvenile idiopathic arthritis (categories of enthesitis related arthritis or juvenile psoriatic arthritis) * participants must have weight of at least 10 kilograms (kg), age starting at 2 years for participants with juvenile psoriatic arthritis and starting at 6 years for participants with enthesitis related arthritis * participants must have all immunizations up-to-date in agreement with current immunization guidelines, in the opinion of the investigator exclusion criteria: * participants must not have active or history of inflammatory bowel disease * participants must not have active uveitis * participants must not have active or latent tuberculosis * participants must not have an active infection * participants must not have concurrent use of biologic agents for the treatment of the juvenile idiopathic arthritis
population pharmacokinetics and dosage individualization of oral pulmonary vasodilators in pphn

Conditions: Persistent Pulmonary Hypertension of the Newborn

Summary: the use of bosentan, sildenafil and tadalafil in neonates with persistent pulmonary hypertension (pphn) depends mostly on the empirical experience of pediatricians. moreover, the recommended dose of those three drugs in treating pphn remains controversial. therefore, our aim is to study the pharmacokinetics and pharmacodynamics of bosentan, sildenafil and tadalafil in neonates of pphn then dose a tailor-made therapeutic regimen.


Eligibility criteria:
inclusion criteria: * age: postnatal age ≤ 28 days; * patients have been diagnosed with pphn; * bosentan, sildenafil and/or tadalafil used as part of regular treatment. * parental written consent exclusion criteria: * expected survival time less than the treatment cycle; * major congenital malformations; * undergoing surgery within the first week of life; * receiving other systemic trial drug therapy; * other factors that the researcher considers unsuitable for inclusion.
validation of receptor occupancy simulation

Conditions: Dopamine Receptor Occupancy; Medication Satisfaction; Prolactin Level; Schizophrenia

Summary: * to estimate dopamine receptor occupancy by aripiprazole using computer simulation * to measure dopamine receptor occupancy by aripiprazole in patients treated with the antipsychotics * to validate the simulation result by comparing the receptor occupancy from the simulation with that from the patients


Eligibility criteria:
inclusion criteria: * clinical diagnosis of schizophrenia * treated with aripiprazole or risperidone * no change in dose of antipsychotics for at least 6 weeks * total panss score should be below 80 exclusion criteria: * other psychiatric disorders rather than schizophrenia * history of head trauma * positive in urine hcg * on antidepressant, anticholinergics or mood stabilizer
pin size influence the incidence of knee pain

Conditions: Pain

Summary: it has been the investigators observation that large diameter traction pins cause more postoperative knee pain than smaller traction pins. to the investigators knowledge, no study to date has identified knee pain as a consequence of traction pin placement. furthermore, no study has identified whether pin size has an effect on the incidence of postoperative knee pain. the goal of the present study is to establish whether use of temporary skeletal traction is associated with subsequent knee pain and to determine whether traction pin size influences the incidence and/or magnitude of knee pain. objective #1: determine whether pin size influences the incidence and/or severity of postoperative knee pain in patients who undergo temporary skeletal traction. hypothesis: larger traction pins are associated with an increase in both the incidence and severity of postoperative knee pain. objective#2: determine whether pin size affects musculoskeletal function in the postoperative period. hypothesis: there is no difference between small and large traction pins in postoperative musculoskeletal function.


Eligibility criteria:
inclusion criteria: * male and female adults * at least 18 years old * injury (pelvic, acetabular, or femoral fracture) requiring temporary skeletal traction. exclusion criteria: * neurovascular compromise. * ipsilateral fractures presenting contraindication to skeletal traction * patients who are non-ambulatory. * patients less than 18 years of age. * patients who do not speak english. * ipsilateral ligamentous knee injury
long-term extension study of pitavastatin in patients with primary hypercholesterolemia or combined dyslipidemia

Conditions: Hypercholesterolemia; Dyslipidemia

Summary: this study is a long-term follow-up protocol for patients who participated in study nk-104-3.01eu or study nk-104-3.02eu.

patients from the nk-104-3.01eu and nk-104-3.02eu studies will continue to receive either pitavastatin or the comparator statin for 1 year.

Eligibility criteria:
inclusion criteria: * patients have completed 12 weeks of treatment in study nk-104-301 (nct00249249) or nk-104-302 (nct00309777) * patients who have not developed any treatment emergent and, in the opinion of the investigator, related adverse event (ae) of clinical significance where the investigator is uncomfortable with continuing the patient on therapy with pitavastatin. * patients who have been following a fat and cholesterol restrictive diet. exclusion criteria: * any conditions which may cause secondary dyslipidemia should be reassessed at the beginning of the follow-up study. * uncontrolled diabetes mellitus should be reassessed at the beginning of the follow-up study. * abnormal pancreatic, liver, or renal function * abnormal serum alat/sgpt/alt, asat/sgot/ast, or creatine kinase (ck) above the pre-specified level * significant heart disease

Keywords: kowa hypercholesterolemia dyslipidemia pitavastatin nk-104 hypercholesterolemia or combined dyslipidemia
complex all-comers and patients with diabetes or prediabetes, treated with xience sierra everolimus-eluting stents

Conditions: Acute Coronary Syndrome; Angina Pectoris; Angina, Unstable; Myocardial Infarction; Coronary Artery Disease; Coronary Stenosis; Coronary Restenosis

Summary: drug eluting stents (des) are widely used for treatment of coronary artery lesions. the xience sierra stent has a refined design of the metal stent backbone and is used in patients with various clinical syndromes and in different lesions. clinical outcome of patients with previously unknown (silent) diabetes and prediabetes is of increasing interest since the latter group has recently shown to be associated with a significant risk of adverse cardiovascular events after treatment with contemporary des. outcome data in a population of high-risk all-comer patients, including many patients with diabetes mellitus and prediabetes, would be of great interest, but such data are not available yet. in addition, there is a lack of data in a general all-comer population. therefore, the coastline study will primarily assess the safety and efficacy of the xience sierra stent in a general all-comer population as well as a high-risk all-comer population.


Eligibility criteria:
inclusion criteria: * \>18 years * requiring pci and treated with xience sierra * capable of providing informed consent exclusion criteria: * known intolerance to components of the study des or antithrombotic/anticoagulant therapy * planned elective surgery necessitating interruption of dual antiplatelet therapy (dapt) \< 3 months * patient is known to be pregnant, unlikely to adhere to follow-up or expected live \< 1 year

Keywords: drug-eluting stent durable polymer everolimus all comers population high-risk all comers target vessel failure coronary artery disease
impact of perinatal anaesthesia and analgesia on neurocognitive outcomes in early childhood

Conditions: Anaesthesia; Neurodevelopment

Summary: this study aims to determine the impact of perinatal exposure to anaesthesia and analgesia on neurocognitive outcomes in early childhood by analyzing neurocognitive data already obtained from the local prospective observational cohort study: growing up in singapore towards healthy outcomes (gusto). we hypothesize that: 1. perinatal exposure to anaesthesia and analgesia is associated with poorer neurocognitive outcomes at 6, 18, 24 and 36 months. 2. maternal anxiety and depression during the antenatal and post-partum period is associated with poorer neurocognitive outcomes at 6, 18 24 and 36 months.

early exposure to general anesthesia is associated long-term neurocognitive and behavioral abnormalities. however the impact of obstetric and perinatal exposure to anaesthesia and analgesia on long term neurocognitive outcomes in the absence of concurrent events (e.g. fetal hypoxia) is unknown. we aim to determine the impact of perinatal exposure to anaesthesia and analgesia on neurocognitive outcomes in early childhood by analyzing information already obtained from the local prospective observational cohort study: growing up in singapore towards healthy outcomes (gusto). gusto is a large prospective cohort trial currently conducted in singapore examining maternal and neonatal outcomes including metabolic, psychological and developmental outcomes. information on infants' neurocognitive outcomes up to 24 months old are already available and we will correlate these outcomes to 1. the infants' perinatal exposure to anaesthesia and analgesia, as obtained from hospital records, and 2. maternal anxiety and depression, as observed from analysis of questionnaires already available from gusto. we hypothesize that: 1. perinatal exposure to anaesthesia and analgesia is associated with poorer neurocognitive outcomes at 6, 18, 24 and 36 months. 2. maternal anxiety and depression during the antenatal and post-partum period is associated with poorer neurocognitive outcomes at 6, 18 24 and 36 months.

Eligibility criteria:
inclusion criteria: infants who are enrolled in the neurocognitve arm of the gusto study (growing up in singapore towards healthy outcomes). exclusion criteria: no information available on previous exposure (maternal exposure in utero, perinatal and postnatal exposure) to general anaesthesia, spinal or epidural anaesthesia.

Keywords: neurodevelopment general anaesthesia infants epidural spinal anxiety and depression
kava kava for the treatment of generalized anxiety disorder (gad)

Conditions: Anxiety Disorders

Summary: the purpose of this study is to evaluate the safety and effectiveness of the herbal medicine kava kava for the treatment of generalized anxiety disorder (gad).

kava kava (kav) is a plant-derived treatment widely used in europe to treat anxiety disorders. several studies suggest that kav may be effective in reducing anxiety symptoms; however, trial data are limited. this study will compare kav, the drug venlafaxine-xr (ven), and placebo for the treatment of gad. this study will last 10 weeks. participants will be randomly assigned to receive kav, ven, or placebo for 8 weeks. participants will then undergo a 1-week tapering of their medication followed by an additional week of observation. self-report scales and questionnaires will be used to assess the anxiety, depression, and functional impairment of participants. side effects, vital signs, and laboratory measures will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * diagnosis of generalized anxiety disorder (gad)

Keywords: kava complementary therapies medicine, herbal
whey protein micelles and thermogenesis in overweight subjects

Conditions: Overweight

Summary: the main objective of the trial is to measure the thermogenic effect of two different doses of whey protein microgels. it will be a randomized crossover double-blind design conducted in 20 subjects.

primary objective and outcome: the primary objective of the trial is to measure the thermogenic effect of two different doses of whey protein microgels (wpm). secondary objectives and outcomes: explore the mechanism of action of wpm on thermogenesis including: protein turnover in response to the dose and the source of protein (wpm versus casein) insulinemic and glycemic response to the dose and source of protein (wpm versus casein) design: the proposed study is a randomized double-blind, placebo-controlled, single center, crossover design. at the start of the study, subjects will be randomly assigned to 4 different groups in a crossover design, where they will be asked to consume a beverage containing product 1: 0g of protein (maltodextrin control) product 2: 30g of wpm product 3: 50g of wpm product 4: 50g of micellar casein (mc) number of subjects: the number of subjects will be 15. sufficient subjects should be recruited to provide a 30% drop-out rate. therefore 20 subjects will be needed including drop-outs.

Eligibility criteria:
inclusion criteria: overweight (bmi range between 25.0 and 29.9 kg per m2 healthy having obtained his/her subjects over 20 year informed consent. exclusion criteria: chronic or acute diseases affecting protein metabolism (diabetes, renal insufficiency, cvd, liver disease), dyslipidemia history of varicose or venous stases recent major surgery (3 months) history of major gastro-intestinal surgery (gastric bypass, intestinal resection etc...) malabsorption disorders history of cancer within the past year significant weight loss during the last 3 months food allergies, especially cow milk protein. pregnancy or lactation special diets especially vegetarian, high protein (≥ 1.6 g/kg) or weight loss program abnormal food frequency questionnaire aversion to vanilla or chocolate aromas smoking moderate to intense physical activity \> 2 hours/week hematocrit \<40 for males and \< 36 for females blood donation within 3 months of study start and 3 months after study end regular consumption of medication and supplements i.e. any treatment affecting thermogenesis or nutrient metabolism in general such as corticosteroids, insulin, androgens, antibiotics and nutritional supplements (multivitamins, protein shakes). have a high alcohol consumption (more than 1 drink/day) consumption of illicit drugs subject who cannot be expected to comply with the study procedures, including consuming the test products. currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study.

Keywords: whey protein microgels thermogenesis
intense pulsed light study for dry eye disease

Conditions: Dry Eyes Chronic

Summary: this study will evaluate the efficacy of intense pulsed light (ipl) therapy for the treatment of dry eye disease. one eye of the participant will be randomized to receive the ipl treatment.

dry eye disease (ded) affects tears and the front surface of the eye. patients who have ded can experience symptoms of discomfort, blurry vision, redness, and pain. ded can also cause tears to become unstable which could result in damage to the front surface of the eye. there are two types of ded. the one the investigators are studying is called evaporative dry eye disease. this type of ded occurs because the pores on the eyelids are not functioning properly. in preliminary studies, a new treatment called intense pulsed light (ipl) has shown promise to reduce signs and symptoms of evaporative ded. ipl is a non-invasive and non-laser light treatment that was approved in 1995 by the fda for dermatology. it is commonly used for treatment of facial rosacea, acne, and hair, wrinkle and lesion removal. it is not currently approved for the treatment of dry eye disease. this treatment is thought to provide relief of evaporative ded symptoms and improve the expression of the pores on the edge of the eyelid.

Eligibility criteria:
inclusion criteria: * willing and able to provide informed consent; * diagnosed with evaporative dry eye disease with symptoms for 6 months or more; * able and willing to comply with follow-up visits, phone calls and intense pulsed light treatments; * agree to using an effective method of birth control during the course of the study; * agree to continue current dry eye treatments during the course of the study; * fitzpatrick skin scale of 1 (very fair) to 4 (olive) as determined by an investigator. exclusion criteria: * darker skinned individuals defined by the fitzpatrick scale 5 and 6 as determined by an investigator; * neurotrophic keratitis; * ectropion, trauma, or any other lid abnormalities; * previous diagnosis of stevens johnson syndrome or graft versus host disease; * ocular burn, active ocular infection, or active ocular inflammation; * currently pregnant or trying to become pregnant in the next 5 months; * systemic conditions or currently taking medications which makes light therapy contraindicated (the use of doxycycline is allowed); * tattoos in the treatment area; * patients who have had intense pulsed light therapy, lipiflow or meibothermoflo within the past six months; * contact lens wear more than one time/week or history of refractive surgery; * glaucoma drop use * ophthalmic steroid use within the past 30 days; * punctal plugs if instilled within 30 days of the start of the study; * obvious asymmetry between the two eyes deemed significant by the investigators (such as punctal plugs or cautery in only one eye, etc); * history of a trabeculectomy or tube surgery; * uncontrolled ocular or systemic disease; * ocular or eyelid surgery within the last 6 months; * any condition which leads the investigator to believe that the patient cannot comply with the study requirements and/or the patient may be placed at risk with participation.
thoracolumbar interfascial plane block versus bilateral erector spinae plane block in lumbar laminectomy

Conditions: Postoperative Pain; Lumbar Laminectomy; Thoracolumbar Interfascial Plane Block; Erector Spinae Plane Block; Ultrasound

Summary: the aim of this prospective randomized trial is to compare the efficacy ultrasound guided thoracolumbar interfascial plane block versus bilateral ultrasound guided erector spinae plane block for post-operative pain management after lumbar laminectomy


Eligibility criteria:
inclusion criteria: * seventy cases with herniated lumbar disc scheduled for lumbar single-level or multiple-level lumbar discectomy with american society of anesthesiologists physical status (asa) i or ii aged between 21 and 60 years of both genders. exclusion criteria: 1. body mass index \>32 2. history of relevant allergy to any of the drugs used in the procedure 3. previous lumbar spine surgery or back surgery with planed spinal fixation
the extremities rehabilitation training system for sarcopenic hospitalized aged 80+ years

Conditions: Sarcopenia

Summary: most previous clinical trials that addressed the rehabilitation training system for sarcopenic elderly subjects focused on community-dwelling older adults who were relatively healthy. there is a notable paucity of high-quality research investigating the effects and feasibility of the device for hospitalized or institutionalized older people, who are generally frailer and more severe in functional impairment than those living in the community. moreover, most reported the system were of long-term duration, which typically lasted 3 to 6 months with two sessions per week. it remains unclear whether short-term the device training would be effective for treating sarcopenia. therefore, the investigators aimed to assess the effectiveness of motor-assisted and active resistive upper/lower extremities rehabilitation training system for treating sarcopenia in hospitalized older patients aged 80 years and over.


Eligibility criteria:
inclusion criteria: * sarcopenia defined by the asia working group of sarcopenia (awgs) * agree to participant this study and sign the informed consent * aged 80 years or over exclusion criteria: * patients who could not follow the training plan due to cognitive impairment, emotional problems or any other reasons; * severe heart and lung diseases; * renal insufficiency; * any type of tumor; * bedridden patients